From molecular characteristics to clinical practice: current status and future prospects of immunotherapy for SMARCA4-deficient tumors.
SMARCA4-deficient tumors arise from mutations, deletions, or fusions of the SMARCA4 gene that abrogate the function of its encoded protein BRG1. Defined by profoundly disrupted chromatin remodeling, these tumors carry a dismal prognosis, respond poorly to conventional therapies, and lack any standardized treatment appr...